Solara Active Pharma Sciences Ltd's Q3FY25 Quarter Results
- 25 Jan 2025
Result Summary
- Solara Active Pharma Sciences Ltd reported a 13.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 21.1%.
- Its expenses for the quarter were down by 13.4% QoQ and 36.4% YoY.
- The net profit increased 1.0% QoQ and decreased 102.9% YoY.
- The earnings per share (EPS) of Solara Active Pharma Sciences Ltd stood at 2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 301.80 | 347.27 | 249.18 | -13.1% | 21.1% |
Total Expenses | 293.71 | 339.26 | 461.75 | -13.4% | -36.4% |
Profit Before Tax | 8.09 | 8.01 | -275.34 | 1.0% | -102.9% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | 8.09 | 8.01 | -275.34 | 1.0% | -102.9% |
Earnings Per Share | 2.00 | 2.50 | -76.50 | -20.0% | -102.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Solara Active Pharma Sciences Ltd is a company operating within the pharmaceutical industry. The company specializes in the production and distribution of active pharmaceutical ingredients (APIs). Solara Active Pharma Sciences has been actively involved in manufacturing a variety of APIs, which are key components in the formulation of medications. As of the latest updates available, there are no specific major developments noted for the company. However, it is essential to understand that the pharmaceutical industry is characterized by its dynamic nature, often influenced by regulatory changes, research advancements, and market demands.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Solara Active Pharma Sciences Ltd reported a total income of ₹301.80 crores. This represents a decrease of 13.1% from the previous quarter (Q2FY25), where the total income was ₹347.27 crores. Comparing year-over-year (YoY) performance, the total income has increased by 21.1%, up from ₹249.18 crores in Q3FY24. This rise over the year indicates growth in the company's revenue streams, despite the quarter-over-quarter (QoQ) decline observed.
Profitability
For Q3FY25, Solara Active Pharma Sciences Ltd recorded a profit before tax of ₹8.09 crores, slightly higher than the ₹8.01 crores reported in Q2FY25, marking a QoQ increase of 1.0%. Year-over-year, there is a notable turnaround from a loss of ₹275.34 crores in Q3FY24 to a profit of ₹8.09 crores in Q3FY25. This change reflects a significant improvement in profitability over the year. The profit after tax aligns with the profit before tax, as the tax expense for the period is reported as ₹0.00 crores across the quarters. Earnings per share (EPS) for Q3FY25 is ₹2.00, down by 20.0% from ₹2.50 in Q2FY25, yet it shows a substantial recovery from a negative EPS of ₹76.50 in Q3FY24.
Operating Metrics
Solara Active Pharma Sciences Ltd’s total expenses for Q3FY25 amounted to ₹293.71 crores, which is a 13.4% decrease from ₹339.26 crores in Q2FY25. This reduction in expenses could be indicative of cost management efforts. Year-over-year, the expenses have decreased by 36.4% from ₹461.75 crores in Q3FY24, aligning with the improved profitability metrics. The company’s financial performance demonstrates a marked YoY improvement, with a focus possibly on operational efficiency, as evidenced by the significant reduction in expenses and the shift from a loss to a profit.
